SureTrader Advertisement
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

RXII RSS Feed
Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator: Inoviorulez
Search This Board:
Last Post: 7/29/2016 4:13:33 PM - Followers: 137 - Board type: Free - Posts Today: 16

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.
 

 



RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.
 

 



This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...

NEWS

June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

http://finance.yahoo.com/news/rxi-pharmaceuticals-strengthens-intellectual-property-110200033.html

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-sustained-effect-120200746.html

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
 
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%
 



http://www.rxipharma.com/

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RXII
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#3640  Sticky Note Rxi Pharmaceuticals (RXII) Research Report 2016 Inoviorulez 06/19/16 09:15:20 AM
#3791   Barrier Therapeutics which Geert sold for $148M sold Titan V 07/29/16 04:13:33 PM
#3790   Tang really did a number to this company The Other Guy 07/29/16 02:57:52 PM
#3789   I agree. However, just to be on the Titan V 07/29/16 02:46:38 PM
#3788   I'm glad to see this released sooner than The Other Guy 07/29/16 02:19:31 PM
#3787   Most importantly compared to 7% placebo effectiveness million_dollar_mafia 07/29/16 01:50:05 PM
#3786   I'm against a buyout because the problem is Inoviorulez 07/29/16 01:41:31 PM
#3785   Good results for a 7 week treatment period, Inoviorulez 07/29/16 01:38:32 PM
#3784   Lolol wouldn't that be something. Auto retirement million_dollar_mafia 07/29/16 01:35:44 PM
#3783   Agreed. And just a thought, with only 6.5M Titan V 07/29/16 01:31:23 PM
#3782   I agree that RXII is a low risk The Other Guy 07/29/16 01:04:47 PM
#3781   Diphenylcyclopropenone Ointment for the Treatment of Common Warts Titan V 07/29/16 12:59:34 PM
#3780   I also recall in 2015 Dr. Cauwenbergh said Titan V 07/29/16 12:51:03 PM
#3779   They've hired an investment bank (Griffin) to look The Other Guy 07/29/16 12:41:08 PM
#3778   Yup. Titan V 07/29/16 10:42:02 AM
#3777   One name missing in this group is Johnson The Other Guy 07/29/16 10:27:14 AM
#3776   Our little $15M market cap company getting mention The Other Guy 07/29/16 09:47:25 AM
#3775   Keloid Treatment Market Revenue and Value Chain 2016-2026 Titan V 07/28/16 11:56:56 PM
#3774   Agreed! Titan V 07/28/16 08:42:13 PM
#3773   The best RXII "report" out there is the The Other Guy 07/28/16 06:52:17 PM
#3772   Shakin the tree. million_dollar_mafia 07/28/16 03:30:24 PM
#3771   Global Alopecia Therapeutics Pipeline Review, H1 2016 - Titan V 07/28/16 02:30:29 PM
#3770   Age Related Macular Degeneration Pipeline Landscape and Therapeutics Titan V 07/28/16 02:12:50 PM
#3769   Not subscribed either. If only these reports/journals were cheap! Titan V 07/28/16 02:07:46 PM
#3768   Do you have the section regarding RXi? I'm million_dollar_mafia 07/28/16 02:04:22 PM
#3767   Proliferative Vitreoretinopathy PVR Therapeutics Development Pipeline Review, H1 Titan V 07/28/16 01:37:25 PM
#3766   Q2 Data on August 11, 2016 tomsylver 07/28/16 08:26:56 AM
#3765   RXIi swing trade n bears move up from Latinachica 07/27/16 05:51:54 PM
#3764   Yea we need news for sure million_dollar_mafia 07/27/16 11:42:39 AM
#3763   Yes, and the 200 day MA appears to The Other Guy 07/27/16 11:21:34 AM
#3762   Seems like RXII is a chart play for million_dollar_mafia 07/27/16 11:13:30 AM
#3761   Poster leak? Volume at 42k half hour The Other Guy 07/27/16 09:54:54 AM
#3760   Let's say the licensing agreement is 80% - The Other Guy 07/26/16 10:50:59 PM
#3759   RXII Swing trade idea. Closed 2.40 (7/26) Latinachica 07/26/16 08:23:59 PM
#3758   Do we know? million_dollar_mafia 07/26/16 07:42:12 PM
#3757   No, but that depends on how much royalty Inoviorulez 07/26/16 07:10:33 PM
#3756   Zacks is not reliable - although I like The Other Guy 07/26/16 04:15:28 PM
#3755   Short interest dropped over 80k at last report The Other Guy 07/26/16 04:13:39 PM
#3754   I think this is why... http://www.investornewswire.com/analyst-views/is-25-price Titan V 07/26/16 03:59:04 PM
#3753   Little surge in volume. Makes one wonder if The Other Guy 07/26/16 01:23:51 PM
#3752   We should have a good indication of the The Other Guy 07/26/16 10:53:36 AM
#3751   I would be surprised if RXII is not The Other Guy 07/24/16 08:56:40 AM
#3750   Well the warts indication alone is probably around Inoviorulez 07/23/16 03:44:54 PM
#3749   Is there a way to estimate potential market The Other Guy 07/23/16 01:03:20 PM
#3748   well at least they will show proof of Inoviorulez 07/23/16 10:20:29 AM
#3747   Just something to consider regarding today's PR. It The Other Guy 07/21/16 01:18:05 PM
#3746   RXi Pharmaceuticals to Present at the 2016 Summer The Other Guy 07/21/16 08:56:01 AM
#3745   Ic so it could have been they just million_dollar_mafia 07/17/16 05:21:18 PM
#3744   Geert said partnerships talk tripled. wildbullus 07/17/16 10:51:52 AM
#3743   But they said they were in active negotiations? million_dollar_mafia 07/17/16 12:44:50 AM
#3742   I think they are waiting for the RXI-109 wildbullus 07/16/16 05:19:44 PM
PostSubject